Zhongyuan Xiehe umbilical cord mesenchymal stem cells anti fibrosis injection is expected to be reviewed in the first half of the second half of the year

According to the announcement on the website of the drug evaluation center of the State Food and drug administration, Zhongyuan Xiehe stem cell bioengineering Co., Ltd (hereinafter referred to as "Zhongyuan Xiehe") ）The "umbilical cord mesenchymal stem cells anti liver fibrosis injection", as a new biological product for treatment, has been accepted on August 2, 2013 Wu Mingyuan introduced to reporters that the clinical phase I and phase II trials are mainly to test the safety of drugs, and the phase III trials are to test the effectiveness of drugs If it passes the phase III trials, it can become a new drug on the market Some securities analysts said in an interview that if stem cell drugs can not be approved quickly, it is difficult to achieve equity incentive performance only relying on the company's current resources In the near future, Zhongyuan Xiehe's share price has been declining continuously In the afternoon of April 17, the company's share price remained at around 23 yuan The price of private placement in the plan for major asset restructuring and related party transactions previously issued by Zhongyuan Xiehe was 24.5 yuan / share Although large shareholders participate in this fixed increase, it does not seem to prevent the stock price from "breaking" ahead of time Zhongyuan Xiehe, a senior executive, told reporters that the company's strategy is to continue to integrate, merge and expand in accordance with the strategic platform of listed companies " The restructuring target of Zhongyuan Xiehe's fixed increase project is Zhicheng biology, which was prepared to go public through IPO In the past few years, Zhicheng biology has accepted the environmental inspection and publicity of listing, but later, due to the indefinite opening of IPO, the company finally gave up IPO and chose to go public through M & A Compared with the listed company Kehua biology in the same industry, although the price to earnings ratio of Zhongyuan Xiehe's acquisition target assets is not high, with the continuous decline of the company's share price, "merger and acquisition is bigger" is embarrassed According to public information, at present, the main profit of COSCO comes from the storage and inspection of liver cells, although Wu Mingyuan said that in the future, COSCO will vigorously expand its cosmetics business But at present, the company's main focus is on the research and development of liver cells On April 12, Zhongyuan Xiehe announced that the Key Laboratory of stem cell regenerative medicine transformation enterprise of Tianjin Heze Stem Cell Technology Co., Ltd., a subsidiary of the company, was recognized as the Key Laboratory of Tianjin enterprise At present, COSCO has hired Massimo Dominici, President of the international cell therapy association, as its consultant It is reported that Massimo Dominici will help the company to increase the talent cultivation and research exchange of liver cell business.